MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%
Last update at 2024-10-30T18:51:00Z
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
Thu 17 Oct 24, 04:04 PMFact Check: Kurt Russell quote saying Biden cheated 2020 election stems from satire
Thu 17 Oct 24, 03:09 PMBio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund
Tue 15 Oct 24, 02:44 PMShould You Continue to Hold Bio-Rad Stock in Your Portfolio?
Tue 01 Oct 24, 02:06 PMWall Street indexes bounce back as investors await inflation data, Fed rate cuts
Tue 10 Sep 24, 12:38 AMNational Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
Fri 06 Sep 24, 03:31 PMLego to replace oil in its bricks with pricier renewable plastic
Thu 29 Aug 24, 02:38 AMReasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
Thu 22 Aug 24, 12:15 PMBio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
Tue 20 Aug 24, 12:30 PMBio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Mon 12 Aug 24, 03:15 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -4704.27300M | 5438.15M | 4907.64M | 2261.08M | 507.36M |
| Minority interest | - | - | - | - | - |
| Net income | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 361.00M |
| Selling general administrative | 827.83M | 879.57M | 800.27M | 824.62M | 834.78M |
| Selling and marketing expenses | - | - | - | - | 1.49M |
| Gross profit | 1567.33M | 1640.66M | 1437.82M | 1257.00M | 1224.36M |
| Reconciled depreciation | 137.30M | 133.80M | 138.10M | 134.20M | 138.10M |
| Ebit | 482.62M | 489.43M | 410.96M | 229.66M | 228.47M |
| Ebitda | 664.49M | 650.01M | 573.57M | 389.99M | 366.55M |
| Depreciation and amortization | 181.87M | 160.58M | 162.62M | 160.33M | 138.09M |
| Non operating income net other | 44.78M | 24.02M | 22.72M | 23.85M | 33.73M |
| Operating income | 482.62M | 489.43M | 410.96M | 229.66M | -108.64100M |
| Other operating expenses | 2319.63M | 2433.11M | 2134.67M | 2082.00M | 2098.24M |
| Interest expense | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M |
| Tax provision | -1076.73800M | 1192.25M | 1101.37M | 502.41M | 147.04M |
| Interest income | 58.00M | 4921.94M | 4491.39M | 30.50M | 26.60M |
| Net interest income | 19.89M | -1.55100M | -21.86100M | 7.08M | 2.64M |
| Extraordinary items | - | - | - | - | 49.00M |
| Non recurring | - | - | - | - | 292.51M |
| Other items | - | - | - | - | - |
| Income tax expense | -1076.73800M | 1192.25M | 1101.37M | 502.41M | 146.36M |
| Total revenue | 2802.25M | 2922.55M | 2545.63M | 2311.66M | 2290.11M |
| Total operating expenses | 1084.71M | 1151.23M | 1026.87M | 1027.34M | 1032.49M |
| Cost of revenue | 1234.92M | 1281.88M | 1107.80M | 1054.66M | 1065.75M |
| Total other income expense net | -5186.88900M | 4948.72M | 4496.68M | 2031.42M | 339.45M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 365.61M |
| Net income applicable to common shares | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 365.61M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 13501.67M | 17775.79M | 12972.62M | 8008.86M | 5603.56M |
| Intangible assets | 332.15M | 253.94M | 199.50M | 145.53M | 125.12M |
| Earning assets | - | - | - | - | - |
| Other current assets | 147.78M | 117.83M | 101.48M | 113.27M | 196.52M |
| Total liab | 3886.41M | 4108.66M | 3092.68M | 2253.80M | 1587.84M |
| Total stockholder equity | 9615.25M | 13667.13M | 9879.94M | 5755.06M | 4015.72M |
| Deferred long term liab | 1770.48M | 3059.08M | 2076.78M | 997.79M | 553.24M |
| Other current liab | 186.20M | 210.67M | 224.94M | 158.49M | 157.41M |
| Common stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00300M |
| Capital stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00300M |
| Retained earnings | 9898.20M | 13507.24M | 9268.01M | 5470.78M | 3722.07M |
| Other liab | 1966.39M | 3417.21M | 2448.88M | 1158.71M | 701.00M |
| Good will | 406.49M | 347.34M | 291.92M | 264.13M | 219.77M |
| Other assets | 94.60M | 0.08M | 0.01M | 40.26M | 70.30M |
| Cash | 434.21M | 470.78M | 662.21M | 660.67M | 431.53M |
| Cash and equivalents | 434.21M | 470.78M | 662.21M | 660.67M | 431.53M |
| Total current liabilities | 568.71M | 680.94M | 631.54M | 905.50M | 449.31M |
| Current deferred revenue | 52.21M | 50.85M | 42.47M | 33.73M | 26.94M |
| Net debt | 763.97M | -459.78000M | -648.14900M | -220.92100M | 7.90M |
| Short term debt | 0.47M | 0.49M | 1.80M | 426.17M | 0.49M |
| Short long term debt | 0.47M | 0.49M | 1.80M | 426.17M | 0.49M |
| Short long term debt total | 1198.18M | 11.00M | 14.06M | 439.75M | 439.43M |
| Other stockholder equity | 183.87M | 335.44M | 329.47M | 371.62M | 340.61M |
| Property plant equipment | 498.61M | 695.75M | 491.37M | 499.34M | 508.69M |
| Total current assets | 3157.98M | 1989.09M | 2139.84M | 2180.16M | 2024.35M |
| Long term investments | 8830.89M | 14387.01M | 9561.14M | 4638.20M | 2655.71M |
| Net tangible assets | 9208.76M | 13065.85M | 9879.94M | 5755.06M | 4020.33M |
| Short term investments | 1362.02M | 404.69M | 334.47M | 459.53M | 418.83M |
| Net receivables | 494.64M | 423.54M | 419.42M | 392.67M | 393.15M |
| Long term debt | 1197.72M | 10.51M | 12.26M | 13.58M | 438.94M |
| Inventory | 719.32M | 572.24M | 622.25M | 554.01M | 584.33M |
| Accounts payable | 329.83M | 418.93M | 362.33M | 287.10M | 264.47M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -466.82200M | -175.55300M | 282.46M | -87.34800M | -46.95800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00300M | 0.00300M | 0.00200M | 0.00300M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 9898.20M | 13507.24M | 9268.01M | 5470.78M | 3722.07M |
| Treasury stock | -263.58600M | -106.29000M | -99.90700M | -38.39700M | -49.12900M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -1770386.40100M | -3058977.33100M | -2076698.27700M | -997707.36400M | -553169.08000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 10343.69M | 15786.71M | 10832.78M | 5828.70M | 3579.21M |
| Capital lease obligations | 189.93M | 212.37M | 211.63M | 211.38M | - |
| Long term debt total | 1197.72M | 10.51M | 12.26M | 13.58M | 438.94M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -994.21100M | -538.17100M | 119.60M | -119.30400M | -68.42900M |
| Change to liabilities | -1335.80000M | 1152.20M | 1103.60M | 460.80M | 75.30M |
| Total cashflows from investing activities | -1207.59300M | -784.43800M | -60.25000M | -208.88900M | -186.97800M |
| Net borrowings | 1185.71M | -3.02000M | -426.93800M | -1.12900M | -2.96100M |
| Total cash from financing activities | 973.58M | -55.42900M | -523.04100M | -22.75800M | -48.68000M |
| Change to operating activities | -26.80000M | 13.93M | 51.68M | 73.50M | -24.20000M |
| Net income | -3627.53500M | 4245.90M | 3806.27M | 1758.67M | 361.00M |
| Change in cash | -36.58900M | -195.98200M | 4.46M | 228.49M | 49.18M |
| Begin period cash flow | 471.13M | 667.12M | 662.65M | 434.16M | 384.98M |
| End period cash flow | 434.54M | 471.13M | 667.12M | 662.65M | 434.16M |
| Total cash from operating activities | 194.45M | 656.52M | 575.33M | 457.90M | 285.49M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 137.30M | 133.80M | 138.13M | 134.24M | 138.09M |
| Other cashflows from investing activities | -100.60000M | -658.92200M | -80.93100M | 0.13M | 11.28M |
| Dividends paid | 68184.00M | 35282.00M | - | 3831.00M | - |
| Change to inventory | -158.80000M | 46.10M | -52.10000M | 24.20M | -12.90000M |
| Change to account receivables | -87.40000M | -20.40000M | -15.00000M | 1.60M | 59.70M |
| Sale purchase of stock | -215.67900M | -49.99800M | -100.00400M | -28.00000M | -48.91200M |
| Other cashflows from financing activities | -212.13400M | -2.41100M | 3.90M | 5.88M | 3.19M |
| Change to netincome | 5254.73M | -3776.37800M | -3457.81500M | -2031.17800M | -295.22000M |
| Capital expenditures | 114.16M | 120.80M | 98.92M | 98.53M | 129.83M |
| Change receivables | 68.18M | 35.28M | 21.49M | 31.67M | 26.38M |
| Cash flows other operating | 126.26M | 621.24M | 553.84M | 426.22M | 259.11M |
| Exchange rate changes | - | -12.63600M | 12.43M | 2.24M | -0.65500M |
| Cash and cash equivalents changes | -39.57000M | -195.98200M | 4.46M | 228.49M | 49.18M |
| Change in working capital | -407.03800M | 13.93M | 51.68M | 55.39M | -37.29800M |
| Stock based compensation | 60.90M | 51.20M | 41.60M | 35.60M | 27.80M |
| Other non cash items | 5272.42M | -3737.11400M | -3420.74400M | -1490.40800M | -323.02000M |
| Free cash flow | 80.29M | 535.72M | 476.41M | 359.37M | 155.67M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIO Bio-Rad Laboratories Inc |
-1.46 0.44% | 330.18 | - | 26.39 | 3.29 | 1.07 | 3.17 | 1499.77 |
| ABT Abbott Laboratories |
0.98 0.86% | 114.38 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
3.39 0.94% | 362.40 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.28 0.32% | 90.61 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.61 0.72% | 83.95 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
| Name | Title | Year Born |
|---|---|---|
| Mr. Norman D. Schwartz | Chairman, CEO & Pres | 1950 |
| Mr. Ilan Daskal | Exec. VP & CFO | 1966 |
| Dr. Andrew J. Last Ph.D. | Exec. VP & COO | 1960 |
| Mr. Michael Crowley | Exec. VP of Global Commercial Operations | 1962 |
| Ms. Dara Grantham Wright | Exec. VP & Pres of Clinical Diagnostics Group | 1976 |
| Mr. Ajit Ramalingam | Sr. VP & Chief Accounting Officer | 1973 |
| Mr. Yong Chung | VP of Investor Relations | NA |
| Mr. Timothy S. Ernst | Exec. VP, Gen. Counsel & Sec. | 1960 |
| Colleen Corey | Sr. VP of Global HR | NA |
| Lee Boyd | Sr. VP of Global Commercial Operations - Asia Pacific | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...